Image Credit: Shutterstock
Dr Reddy’s Laboratories has entered into a binding agreement with Singapore-based Prestige BioPharma for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.
Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer.
The license agreement grants Dr Reddy’s the exclusive rights to commercialise the proposed biosimilar in select countries in Latin America and Southeast Asia. Under this partnership, Prestige BioPharma will be responsible for the sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.
M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, said: “This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.”
